Human immunodeficiency virus type 1 long terminal repeat quasispecies differ in basal transcription and nuclear factor recruitment in human glial cells and lymphocytes.
The generation of genomic diversity during the course of infection has the potential to affect all aspects of HIV-1 replication, including expression of the proviral genome. To gain a better understanding of the impact of long terminal repeat (LTR) sequence diversity on LTR-directed gene expression in cells of the central nervous system (CNS) and immune system, we amplified and cloned LTRs from proviral DNA in HIV-1-infected peripheral blood. Sequence analysis of nineteen LTRs cloned from 2 adult and 3 pediatric patients revealed an average of 33 nucleotide changes (with respect to the sequence of the LAI LTR) within the 455-bp U3 region. Transient expression analyses in cells of neuroglial and lymphocytic origin demonstrated that some of these LTRs had activities which varied significantly from the LAI LTR in U-373 MG cells (an astrocytoma cell line) as well as in Jurkat cells (a CD4-positive lymphocyte cell line). While LTRs which demonstrated the highest activities in U-373 MG cells also yielded high activities in Jurkat cells, the LTRs were generally more active in Jurkat cells when compared to the LAI LTR. Differences in LTR sequence also resulted in differences in transcription factor recruitment to cis-acting sites within the U3 region of the LTR, as demonstrated by electrophoretic mobility shift assays. In particular, naturally occurring sequence variation impacted transcription factor binding to an activating transcription factor/cAMP response element binding (ATF/CREB) binding site (located between the LEF-1 and distal NF-kappaB transcription factor binding sites) that we identified in previous studies of the HIV-1 LTR. These findings suggest that LTR sequence changes can significantly affect basal LTR function and transcription factor recruitment, which may, in turn, alter the course of viral replication in cells of CNS and immune system origin.
Krebs
F C
FC
Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey 17033, USA.
Mehrens
D
D
Pomeroy
S
S
Goodenow
M M
MM
Wigdahl
B
B
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology / Q000821:virology; D000328:Adult; D001254:Astrocytoma; D001483:Base Sequence; D001665:Binding Sites; D015500:Chloramphenicol O-Acetyltransferase / Q000096:biosynthesis; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D017930:Genes, Reporter; D016325:HIV Long Terminal Repeat; D015497:HIV-1 / Q000235:genetics* / Q000502:physiology*; D006801:Humans; D019169:Jurkat Cells; D008214:Lymphocytes / Q000378:metabolism / Q000821:virology*; D051821:Lymphoid Enhancer-Binding Factor 1; D016328:NF-kappa B / Q000378:metabolism; D009457:Neuroglia / Q000378:metabolism / Q000821:virology*; D009687:Nuclear Proteins / Q000378:metabolism*; D015345:Oligonucleotide Probes; D011533:Proviruses / Q000235:genetics / Q000502:physiology; D016415:Sequence Alignment; D014157:Transcription Factors / Q000378:metabolism*; D014158:Transcription, Genetic; D014162:Transfection; D014407:Tumor Cells, Cultured; D014779:Virus Replication
D017362:Cyclic AMP Response Element-Binding Protein; D004268:DNA-Binding Proteins; C497573:LEF1 protein, human; D051821:Lymphoid Enhancer-Binding Factor 1; D016328:NF-kappa B; D009687:Nuclear Proteins; D015345:Oligonucleotide Probes; D014157:Transcription Factors; D015500:Chloramphenicol O-Acetyltransferase